<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DILAUDID- hydromorphone hydrochloride injection, solution </strong><br><strong>DILAUDID HP- hydromorphone hydrochloride injection, solution </strong><br><strong>DILAUDID HP- hydromorphone hydrochloride injection, powder, lyophilized, for solution </strong><br>Purdue Pharma LP<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use DILAUDID<span class="Sup">®</span> INJECTION and DILAUDID-HP<span class="Sup">®</span><br>
	INJECTION safely and effectively. See full prescribing information for DILAUDID<span class="Sup">®</span> INJECTION and DILAUDID-HP<span class="Sup">®</span> INJECTION.<br>
	DILAUDID<span class="Sup">®</span> INJECTION (hydromorphone hydrochloride) DILAUDID-HP<span class="Sup">®</span> INJECTION (hydromorphone hydrochloride)<br>
	CII<br>
	For intravenous, intramuscular and subcutaneous use<br>
	Initial U.S. Approval: January 1984</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold"><span class="Emphasis">WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>, ABUSE, AND MEDICATION ERRORS DILAUDID-HP<span class="Sup">®</span> INJECTION IS FOR USE IN OPIOID-TOLERANT PATIENTS ONLY</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics"><span class="Emphasis">See full prescribing information for complete boxed warning.</span></span></span></h1>
<ul class="Disc">
<li>
<span class="Bold"><span class="Emphasis">Do not confuse DILAUDID-HP INJECTION with standard parenteral formulations of DILAUDID or other opioids, as <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> could result.</span></span><a href="#Section_5"> (5)</a>
</li>
<li>
<span class="Bold"><span class="Emphasis">Hydromorphone is a potent Schedule II opioid agonist. 
Schedule II opioid agonists have the highest potential for abuse and risk of producing <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Ethanol, other opioids, and other central nervous system depressants can potentiate the respiratory-depressant effects of hydromorphone and increase the risk of adverse outcomes, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. 
</span></span><a href="#Section_5.1"> (5.1</a>, <a href="#Section_7.1">7.1)</a>
</li>
</ul>
</div></div>
<div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold"><span class="Emphasis">WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>, ABUSE, AND MEDICATION ERRORS DILAUDID-HP<span class="Sup">®</span> INJECTION IS FOR USE IN OPIOID-TOLERANT PATIENTS ONLY</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics"><span class="Emphasis">See full prescribing information for complete boxed warning.</span></span></span></h1>
<ul class="Disc">
<li>
<span class="Bold"><span class="Emphasis">Do not confuse DILAUDID-HP INJECTION with standard parenteral formulations of DILAUDID or other opioids, as <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> could result.</span></span><a href="#Section_5"> (5)</a>
</li>
<li>
<span class="Bold"><span class="Emphasis">Hydromorphone is a potent Schedule II opioid agonist. 
Schedule II opioid agonists have the highest potential for abuse and risk of producing <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Ethanol, other opioids, and other central nervous system depressants can potentiate the respiratory-depressant effects of hydromorphone and increase the risk of adverse outcomes, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. 
</span></span><a href="#Section_5.1"> (5.1</a>, <a href="#Section_7.1">7.1)</a>
</li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul class="Disc">
<li>DILAUDID INJECTION is an opioid analgesic indicated for the management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> where an opioid analgesic is appropriate. <a href="#Section_1"> (1)</a>
</li>
<li>DILAUDID-HP INJECTION is indicated for the management of moderate-to-severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in opioid-tolerant patients who require higher doses of opioids. <a href="#Section_1"> (1)</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>DILAUDID INJECTION: The usual starting dose is 1 mg to 2 mg <span class="Italics"><span class="Emphasis">subcutaneously</span></span> or <span class="Italics"><span class="Emphasis">intramuscularly</span></span> every 2 to 3 hours as necessary. <a href="#Section_2.3"> (2.3)</a>
</li>
<li>DILAUDID-HP INJECTION should be used only if the amount of hydromorphone required can be delivered accurately with this formulation. <a href="#Section_2.5"> (2.5)</a>
</li>
<li>For patients already receiving opioids, use standard conversion ratio estimates. <a href="#Section_2.4"> (2.4)</a>
</li>
<li>The dose should be adjusted according to the severity of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, as well as the patient's underlying disease state and age. <a href="#Section_2.1"> (2.1</a>, <a href="#Section_2.2">2.2)</a>
</li>
<li>Should intravenous administration be necessary, the injection should be given slowly, over at least 2 to 3 minutes and the usual starting dose is 0.2 to 1 mg. <a href="#Section_2.3.2">(2.3.2)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc">
<li>DILAUDID INJECTION: 1 mg/mL, 2 mg/mL, or 4 mg/mL. <a href="#Section_3">(3)</a>
</li>
<li>DILAUDID-HP INJECTION: 10 mg/mL in 1 mL or 5 mL ampule or 50 mL single-dose vial. <a href="#Section_3">(3)</a>
</li>
<li>DILAUDID-HP INJECTION Sterile Lyophilized Powder: 250 mg of sterile, lyophilized hydromorphone hydrochloride to be reconstituted to provide a solution containing 10 mg/mL. <a href="#Section_3">(3)</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydromorphone, hydromorphone salts, any components of the product, or in any situation where opioids are contraindicated  <a href="#Section_4">(4)</a>
</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the absence of resuscitative equipment or in unmonitored settings; patients with status asthmaticus <a href="#Section_4">(4)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">Gastrointestinal obstruction</span>, especially <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> <a href="#Section_4">(4)</a>
</li>
<li>DILAUDID-HP INJECTION: Patients who are not opioid tolerant <a href="#Section_4">(4)</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>DILAUDID-HP INJECTION is a concentrated formulation of hydromorphone. Do NOT confuse DILAUDID-HP INJECTION with DILAUDID INJECTION. <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> could result. <a href="#Section_5.1">(5.1)</a>
</li>
<li>May cause <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, use with extreme caution in patients at risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, elderly, and debilitated patients. <a href="#Section_5.2">(5.2)</a>
</li>
<li>Abuse of DILAUDID INJECTION and DILAUDID-HP INJECTION poses a hazard of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <a href="#Section_5.3">(5.3)</a>
</li>
<li>Risk of medication errors: Morphine does not convert to hydromorphone on a milligram per milligram basis. Use Table 1 to convert. <a href="#Section_5.1">(5.1)</a>
</li>
<li>Alcohol, other opioids and central nervous system depressants potentiate the respiratory depressant effects of hydromorphone. <a href="#Section_5.4">(5.4)</a>
</li>
<li>Infants born to mothers physically dependent on DILAUDID INJECTION or DILAUDID-HP INJECTION will also be physically dependent and may exhibit respiratory difficulties and withdrawal symptoms. <a href="#Section_5.5">(5.5)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> may be markedly increased in patients with <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions, or preexisting increase in intracranial pressure. <a href="#Section_5.6">(5.6)</a>
</li>
<li>May cause <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, use with caution in patients at increased risk of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and in patients in circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>. <a href="#Section_5.7">(5.7)</a>
</li>
<li>DILAUDID INJECTION and DILAUDID-HP INJECTION contain sodium metabisulfite. There is a risk of anaphylactic symptoms and life-threatening <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in susceptible people. <a href="#Section_5.8">(5.8)</a>
</li>
<li>Use with caution in patients with <span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">biliary tract disease</span> including <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. <a href="#Section_5.9">(5.9)</a>
</li>
<li>Use with caution and in reduced initial doses in the elderly, debilitated, or other patient populations with increased risk of adverse reactions from opioids. <a href="#Section_5.10">(5.10)</a>
</li>
<li>Use with caution in patients with <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span> or other drug dependencies. <a href="#Section_5.11">(5.11)</a>
</li>
<li>May impair the mental and physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. <a href="#Section_5.12">(5.12)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions are <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. <a href="#Section_6">(6)</a> </p>
<p class="Highlighta">  </p>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">To report Suspected Adverse Reactions, contact Purdue Pharma L.P. at 1-888-726-7535 or FDA at 1-800-FDA-1088 or </span></span><span class="Bold"><span class="Italics"><span class="Emphasis"> www.fda.gov/medwatch</span></span></span>. </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Concurrent use of other CNS depressants may cause <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and profound sedation or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. <a href="#Section_7.1">(7.1)</a>
</li>
<li>Mixed agonist/antagonist analgesics may reduce the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of hydromorphone and may precipitate withdrawal symptoms in these patients. <a href="#Section_7.2">(7.2)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Pregnancy: Based on animal data, may cause fetal harm. <a href="#Section_8.1">(8.1)</a>
</li>
<li>Labor and Delivery: Use with caution during labor. <a href="#Section_8.2">(8.2)</a>
</li>
<li>Nursing Mothers: Nursing should not be undertaken while a patient is receiving DILAUDID INJECTION or DILAUDID-HP INJECTION. <a href="#Section_8.3">(8.3)</a>
</li>
<li>Pediatrics: Safety and effectiveness in pediatric patients have not been established. <a href="#Section_8.4">(8.4)</a>
</li>
<li>Geriatrics: Use with caution in elderly patients, initiate dose at low end of dosing range. <a href="#Section_8.5">(8.5)</a>
</li>
<li>Hepatic and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Patients with hepatic and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should be started on a lower starting dose. <a href="#Section_8.6">(8.6</a>, <a href="#Section_8.7">8.7</a>, <a href="#Section_12.2">12.2)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsRevision">Revised: 9/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"></a></h1>
<h1><a href="#section-2" class="toc">BOX WARNING</a></h1>
<h1><a href="#section-2" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-3" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-3.1" class="toc">2.1  General Dosing Considerations</a></h2>
<h2><a href="#section-3.2" class="toc">2.2  Individualization of Dosing</a></h2>
<h2><a href="#section-3.3" class="toc">2.3  Initiation of Therapy in Opioid-Naïve Patients</a></h2>
<h2><a href="#section-3.4" class="toc">2.4  Conversion From Prior Opioid</a></h2>
<h2><a href="#section-3.5" class="toc">2.5  DILAUDID-HP Injection (for use in opioid-tolerant patients only)</a></h2>
<h2><a href="#section-3.6" class="toc">2.6  Administration and Reconstitution</a></h2>
<h1><a href="#section-4" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-5" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-6" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">5.1  Risk of Medication Errors</a></h2>
<h2><a href="#section-6.2" class="toc">5.2  Respiratory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></a></h2>
<h2><a href="#section-6.3" class="toc">5.3  Misuse, Abuse and Diversion of Opioids</a></h2>
<h2><a href="#section-6.4" class="toc">5.4  Interactions with Alcohol and other CNS Depressants </a></h2>
<h2><a href="#section-6.5" class="toc">5.5  Neonatal Withdrawal Syndrome</a></h2>
<h2><a href="#section-6.6" class="toc">5.6  Use in <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span> or <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span></a></h2>
<h2><a href="#section-6.7" class="toc">5.7  Hypotensive Effect</a></h2>
<h2><a href="#section-6.8" class="toc">5.8  Sulfites</a></h2>
<h2><a href="#section-6.9" class="toc">5.9  Use in Pancreatic/<span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">Biliary Tract Disease</span> and Other Gastrointestinal Conditions</a></h2>
<h2><a href="#section-6.10" class="toc">5.10  Special Risk Patients</a></h2>
<h2><a href="#section-6.11" class="toc">5.11  Use in Drug and Alcohol Dependent Patients </a></h2>
<h2><a href="#section-6.12" class="toc">5.12  Use in Ambulatory Patients</a></h2>
<h2><a href="#section-6.13" class="toc">5.13  Parenteral Administration</a></h2>
<h1><a href="#section-7" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc"></a></h2>
<h1><a href="#section-8" class="toc">7  DRUG INTERACTIONS</a></h1>
<h2><a href="#section-8.1" class="toc">7.1  Drug Interactions with other CNS Depressants </a></h2>
<h2><a href="#section-8.2" class="toc">7.2  Interactions with Mixed Agonist/Antagonist Opioid Analgesics </a></h2>
<h2><a href="#section-8.3" class="toc">7.3  Monoamine Oxidase Inhibitors (MAOIs)</a></h2>
<h2><a href="#section-8.4" class="toc">7.4  Anticholinergics</a></h2>
<h1><a href="#section-9" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-9.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-9.2" class="toc">8.2  Labor and Delivery</a></h2>
<h2><a href="#section-9.3" class="toc">8.3  Nursing Mothers</a></h2>
<h2><a href="#section-9.4" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-9.5" class="toc">8.5  Geriatric Use</a></h2>
<h2><a href="#section-9.6" class="toc">8.6  Renal Impairment</a></h2>
<h2><a href="#section-9.7" class="toc">8.7  Hepatic Impairment</a></h2>
<h1><a href="#section-10" class="toc">9  DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-10.1" class="toc">9.1  Controlled Substance</a></h2>
<h2><a href="#section-10.2" class="toc">9.2  Abuse</a></h2>
<h2><a href="#section-10.3" class="toc">9.3  Dependence</a></h2>
<h1><a href="#section-11" class="toc">10  OVERDOSAGE</a></h1>
<h2><a href="#section-11.1" class="toc">10.1  Signs and Symptoms</a></h2>
<h2><a href="#section-11.2" class="toc">10.2  Treatment</a></h2>
<h1><a href="#section-12" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-13" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-13.2" class="toc">12.2  Pharmacokinetics</a></h2>
<h1><a href="#section-14" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-14.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-15" class="toc">14  CLINICAL STUDIES</a></h1>
<h1><a href="#section-16" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-16.1" class="toc">16.1  Safety and Handling Instructions</a></h2>
<h2><a href="#section-16.2" class="toc">16.2  How Supplied</a></h2>
<h2><a href="#section-16.3" class="toc">16.3  Storage</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_00"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">DILAUDID<span class="Sup">®</span> INJECTION (hydromorphone hydrochloride), CII</span></span></p>
<p><span class="Bold"><span class="Emphasis">DILAUDID-HP<span class="Sup">®</span> INJECTION (hydromorphone hydrochloride), CII</span></span></p>
<p><span class="Bold"><span class="Emphasis">For intravenous, intramuscular, and subcutaneous use</span></span></p>
</div>
<div class="Warning">
<a name="Section_0"></a><a name="section-2"></a><p></p>
<h1>BOX WARNING</h1>
<p class="First"><span class="Bold"><span class="Emphasis">WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>, ABUSE, AND MEDICATION ERRORS</span></span></p>
<p><span class="Bold"><span class="Emphasis">DILAUDID-HP INJECTION IS FOR USE IN OPIOID-TOLERANT PATIENTS ONLY</span></span></p>
<p><span class="Bold"><span class="Emphasis">Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine/day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for one week or longer.</span></span></p>
<p><span class="Bold"><span class="Emphasis">DILAUDID-HP INJECTION is a more concentrated solution of hydromorphone than DILAUDID INJECTION, and is for use in opioid-tolerant patients only. Do not confuse DILAUDID-HP INJECTION with standard parenteral formulations of DILAUDID INJECTION or other opioids, as <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> could result.</span></span></p>
<p><span class="Bold"><span class="Emphasis">DILAUDID INJECTION and DILAUDID-HP INJECTION contain hydromorphone, an opioid agonist and a Schedule II controlled substance with an abuse liability similar to other opioid analgesics. DILAUDID INJECTION and DILAUDID-HP INJECTION can be abused in a manner similar to other opioid agonists, legal or illicit. These risks should be considered when administering, prescribing, or dispensing DILAUDID INJECTION and DILAUDID-HP INJECTION in situations where the healthcare professional is concerned about increased risk of misuse, abuse, or diversion.</span></span></p>
<p><span class="Bold"><span class="Emphasis">Schedule II opioid agonists, including morphine, oxymorphone, hydromorphone, oxycodone, fentanyl and methadone, have the highest potential for abuse and risk of producing fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> due to <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Ethanol, other opioids, and other central nervous system depressants (e.g., sedative-hypnotics, skeletal muscle relaxants) can potentiate the respiratory-depressant effects of hydromorphone and increase the risk of adverse outcomes, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-2"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<p class="First">DILAUDID INJECTION is indicated for the management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in patients where an opioid analgesic is appropriate.</p>
<p>DILAUDID-HP INJECTION is indicated for the management of moderate-to-severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in opioid-tolerant patients who require higher doses of opioids. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-3"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-3.1"></a><p></p>
<h2>2.1  General Dosing Considerations</h2>
<p class="First"><span class="Bold"><span class="Emphasis">Take care when prescribing and administering Dilaudid and Dilaudid-HP Injection to avoid dosing errors due to <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> between the different concentrations and between mg and mL, which could result in accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Take care to ensure the proper dose is communicated and dispensed. When writing prescriptions, include both the total dose in mg and the total volume of the dose. </span></span></p>
<p>Selection of patients and administration of Dilaudid and Dilaudid-HP injection should be governed by the same principles that apply to the use of similar opioid analgesics to treat patients with acute or <span class="product-label-link" type="condition" conceptid="436096" conceptname="Chronic pain">chronic pain</span>, and depends upon a comprehensive assessment of the patient. Individualize treatment in every case, using non-opioid analgesics, opioids on an as-needed basis and/or combination products, and chronic opioid therapy in a progressive plan of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality, and the American <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Society.</p>
<p>The nature of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (severity, frequency, etiology, and pathophysiology), as well as the medical status of the patient, will affect selection of the starting dosage. Opioid analgesics, including DILAUDID INJECTION and DILAUDID-HP INJECTION, have a narrow therapeutic index in certain patient populations, especially when combined with CNS depressant drugs, and should be reserved for cases where the benefits of opioid <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> outweigh the known risks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-3.2"></a><p></p>
<h2>2.2  Individualization of Dosing</h2>
<p class="First">Initiate the dosing regimen for each patient individually, taking into account the patient’s prior analgesic treatment. Give attention to the following:</p>
<ul class="Disc">
<li>the age, general condition, and medical status of the patient;</li>
<li>the patient's degree of opioid tolerance;</li>
<li>the daily dose, potency, and specific characteristics of the opioid the patient has been taking previously; </li>
<li>concurrent medications</li>
<li>the type and severity of the patient’s <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li>risk factors for abuse or addiction; including whether the patient has a previous or current <span class="product-label-link" type="condition" conceptid="4279309" conceptname="Substance abuse">substance abuse</span> problem, a family history of <span class="product-label-link" type="condition" conceptid="4279309" conceptname="Substance abuse">substance abuse</span>, or a history of mental illness or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>;</li>
<li>the balance between <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> control and adverse reactions.</li>
</ul>
<p>Periodic reassessment after the initial dosing of DILAUDID INJECTION and DILAUDID-HP INJECTION is required. If <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> management is not satisfactory, and opioid-induced adverse events are tolerable, the hydromorphone dose may be increased gradually. If excessive opioid side effects are observed early in the dosing interval, reduce the hydromorphone hydrochloride dose. If this results in breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at the end of the dosing interval, the dosing interval may need to be shortened. Dose titration should be guided more by the need for <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and the severity of adverse events than the absolute dose of opioid employed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-3.3"></a><p></p>
<h2>2.3  Initiation of Therapy in Opioid-Naïve Patients</h2>
<p class="First"><span class="Bold"><span class="Emphasis">Always initiate dosing in opioid-naïve patients using Dilaudid Injection. Never administer Dilaudid-HP injection to opioid-naïve patients. </span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.1"></a><a name="section-3.3.1"></a><p></p>
<h3>2.3.1 Subcutaneous or Intramuscular Administration</h3>
<p class="First">The usual starting dose of Dilaudid Injection is 1 mg to 2 mg every 2 to 3 hours as necessary. Depending on the clinical situation, the initial starting dose may be lowered in patients who are opioid naïve. Adjust the dose according to the severity of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, the severity of adverse events, as well as the patient's underlying disease and age. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.2"></a><a name="section-3.3.2"></a><p></p>
<h3>2.3.2 Intravenous Administration</h3>
<p class="First">The initial starting dose is 0.2 to 1 mg every 2 to 3 hours.  Intravenous administration should be given <span class="Bold"><span class="Emphasis">slowly</span></span>, over at least 2 to 3 minutes, depending on the dose. Titrate the dose to achieve acceptable <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and tolerable adverse events.  The initial dose should be reduced in the elderly or debilitated and may be lowered to 0.2 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.3"></a><a name="section-3.3.3"></a><p></p>
<h3>2.3.3 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h3>
<p class="First">Start patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on one-fourth to one-half the usual DILAUDID INJECTION starting dose depending on the extent of impairment <span class="Italics"><span class="Emphasis">[see CLINICAL PHARMACOLOGY, Pharmacokinetics <a href="#Section_12.2">(12.2)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.4"></a><a name="section-3.3.4"></a><p></p>
<h3>2.3.4 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h3>
<p class="First">Start patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on one-fourth to one-half the usual DILAUDID INJECTION starting dose depending on the degree of impairment <span class="Italics"><span class="Emphasis">[see CLINICAL PHARMACOLOGY, Pharmacokinetics <a href="#Section_12.2">(12.2)</a>]</span></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.4"></a><a name="section-3.4"></a><p></p>
<h2>2.4  Conversion From Prior Opioid</h2>
<p class="First">Use the equianalgesic dose table below (Table 1) as a guide to determine the appropriate dose of DILAUDID INJECTION.  Convert the current total daily amount(s) of opioid(s) received to an equivalent total daily dose of DILAUDID INJECTION and reduce by one-half due to the possibility of incomplete cross tolerance. Divide the new total amount by the number of doses permitted based on dosing interval (e.g., 8 doses for every-three-hour dosing).  Titrate the dose according to the patient's response.  For opioids not in Table 1, first estimate the daily amount of morphine that is equivalent to the current total daily amount of other opioid(s) received, then use Table 1 to find the approximate equivalent total daily dose of DILAUDID INJECTION.</p>
<table border="0" cellpadding="0" cellspacing="0" width="85%">
<caption><span>Table 1. OPIOID ANALGESIC EQUIVALENTS WITH APPROXIMATELY EQUIANALGESIC POTENCY FOR CONVERSION TO DILAUDID INJECTION*</span></caption>
<thead><tr class="Botrule First Last">
<th class="Lrule Rrule Toprule" align="left">DRUG SUBSTANCE</th>
<th class="Rrule Toprule" align="center">PARENTERAL DOSE</th>
<th class="Rrule Toprule" align="center">ORAL DOSE</th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Toprule" colspan="3">* Dosages, and ranges of dosages represented, are a compilation of estimated equipotent dosages from published references comparing opioid analgesics in cancer and severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. </td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule Toprule" align="left">Morphine sulfate</td>
<td class="Rrule Toprule" align="center">10 mg</td>
<td class="Rrule Toprule" align="center">40 – 60 mg</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">Hydromorphone HCl </td>
<td class="Rrule Toprule" align="center">1.3 – 2 mg</td>
<td class="Rrule Toprule" align="center">6.5 – 7.5 mg</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">Oxymorphone HCl </td>
<td class="Rrule Toprule" align="center">1 – 1.1 mg</td>
<td class="Rrule Toprule" align="center">6.6 mg</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">Levorphanol tartrate </td>
<td class="Rrule Toprule" align="center">2 – 2.3 mg</td>
<td class="Rrule Toprule" align="center">4 mg</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">Meperidine HCl (Pethidine HCl) </td>
<td class="Rrule Toprule" align="center">75 – 100 mg</td>
<td class="Rrule Toprule" align="center">300 – 400 mg</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">Methadone HCl </td>
<td class="Rrule Toprule" align="center">10 mg</td>
<td class="Rrule Toprule" align="center">10 – 20 mg</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">Nalbuphine HCl </td>
<td class="Rrule Toprule" align="center">10 – 12 mg</td>
<td class="Rrule Toprule" align="center">–</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule Toprule" align="left">Butorphanol tartrate</td>
<td class="Rrule Toprule" align="center">1.5 – 2.5 mg</td>
<td class="Rrule Toprule" align="center">–</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.5"></a><a name="section-3.5"></a><p></p>
<h2>2.5  DILAUDID-HP Injection (for use in opioid-tolerant patients only)</h2>
<p class="First"><span class="Bold"><span class="Emphasis">Do not use DILAUDID-HP for patients who are not tolerant to the respiratory depressant or sedating effects of opioids.</span></span> Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine/day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for one week or longer.</p>
<p>Use DILAUDID-HP ONLY for patients who require the higher concentration and lower total volume of DILAUDID-HP.</p>
<p>Because of its high concentration, the delivery of precise doses of DILAUDID-HP INJECTION may be difficult if low doses of hydromorphone are required. Therefore, use DILAUDID-HP INJECTION only if the amount of hydromorphone required can be delivered accurately with this formulation.</p>
<p>Base the starting dose for DILAUDID-HP INJECTION on the prior dose of DILAUDID INJECTION or on the prior dose of an alternate opioid as described above in Section 2.4 Conversion From Prior Opioid and Table 1.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.6"></a><a name="section-3.6"></a><p></p>
<h2>2.6  Administration and Reconstitution</h2>
<p class="First">Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. A slight yellowish discoloration may develop in DILAUDID INJECTION and DILAUDID-HP INJECTION ampules. No loss of potency has been demonstrated. DILAUDID INJECTION and DILAUDID-HP INJECTION are physically compatible and chemically stable for at least 24 hours at 25°C, protected from light in most common large-volume parenteral solutions.</p>
<p><span class="Italics"><span class="Emphasis">500 mg/50 mL Vial</span></span><br>
								To use this single dose presentation, do not penetrate the stopper with a syringe. Instead, remove both the aluminum flipseal and rubber stopper in a suitable work area such as under a laminar flow hood (or equivalent clean air compounding area). The contents may then be withdrawn for preparation of a single, large-volume parenteral solution. Discard any unused portion in an appropriate manner.</p>
<p><span class="Italics"><span class="Emphasis">Reconstitution of Sterile Lyophilized DILAUDID-HP INJECTION 250 mg</span></span><br>
								Reconstitute immediately prior to use with 25 mL of Sterile Water for Injection USP to provide a sterile solution containing 10 mg/mL of hydromorphone hydrochloride.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-4"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">DILAUDID INJECTION:<br>
						Each 1 mL colorless ampule contains 1 mg/mL, 2 mg/mL, or 4 mg/mL of hydromorphone hydrochloride in a sterile, aqueous solution. </p>
<p>DILAUDID-HP INJECTION (for use in opioid-tolerant patients only):<br>
						Each amber ampule and amber single-dose vial contains 10 mg/mL of hydromorphone hydrochloride in a sterile, aqueous solution <span class="Underline"><span class="Emphasis">and is available in 1 mL or 5 mL ampules</span></span> or in 50 mL single-dose vials<span class="Sup">†</span>.</p>
<p>DILAUDID-HP INJECTION Sterile Lyophilized Powder:<br>
						Each amber, single-dose vial<span class="Sup">†</span> contains 250 mg of sterile, lyophilized hydromorphone hydrochloride to be reconstituted with 25 mL of Sterile Water for Injection USP to provide a solution containing 10 mg/mL.</p>
<p><span class="Bold"><span class="Emphasis"><span class="Sup">†</span>The Stoppers Of These Products Contain Natural Rubber Latex.</span></span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-5"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First">Both DILAUDID INJECTION and DILAUDID-HP INJECTION are contraindicated:</p>
<ul class="Disc">
<li>In patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydromorphone, hydromorphone salts, any other components of the product, or sulfite-containing medications <span class="Italics"><span class="Emphasis">[see WARNINGS AND PRECAUTIONS, Sulfites <a href="#Section_5.8">(5.8)</a>].</span></span>
</li>
<li>In any situation where opioids are contraindicated, e.g., in patients with <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the absence of resuscitative equipment or in unmonitored settings; or patients with acute or severe bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. </li>
<li>In patients with, or at risk of developing, <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">gastrointestinal obstruction</span>, especially <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> because hydromorphone diminishes the propulsive peristaltic wave in the gastrointestinal tract and may prolong the obstruction.</li>
</ul>
<p>DILAUDID-HP INJECTION is contraindicated in patients who are not opioid tolerant <span class="Italics"><span class="Emphasis">[see WARNINGS AND PRECAUTIONS <a href="#Section_5.1">(5.1)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-6"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-6.1"></a><p></p>
<h2>5.1  Risk of Medication Errors</h2>
<p class="First">DILAUDID-HP INJECTION is a 10 mg/mL concentrated solution of hydromorphone, and is intended for use in opioid-tolerant patients only. Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine/day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for one week or longer.</p>
<p>Do not confuse DILAUDID-HP INJECTION with standard parenteral formulations of DILAUDID INJECTION (1 mg/mL, 2 mg/mL, 4 mg/mL) or other opioids, as <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> could result.</p>
<p><span class="Bold"><span class="Emphasis">Morphine does not convert to hydromorphone on a mg per mg basis. Use Table 1 when converting a patient from morphine to hydromorphone to avoid errors that can lead to <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-6.2"></a><p></p>
<h2>5.2  Respiratory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is the chief hazard of DILAUDID INJECTION and DILAUDID-HP INJECTION. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> occurs most frequently in the elderly, in the debilitated, and in those suffering from conditions accompanied by <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> or <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, or upper airway obstruction, in whom even moderate therapeutic doses may dangerously decrease pulmonary ventilation. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is also a particular problem following large initial doses in non opioid-tolerant patients or when opioids are given in conjunction with other agents that depress respiration.</p>
<p>Use DILAUDID INJECTION and DILAUDID-HP INJECTION with extreme caution in patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> or <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span>, patients having a substantially decreased respiratory reserve, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, or preexisting <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. In such patients, even usual therapeutic doses of opioid analgesics may decrease respiratory drive while simultaneously increasing airway resistance to the point of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. Consider using non-opioid analgesics, and administer DILAUDID only under careful medical supervision at the lowest effective dose in such patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-6.3"></a><p></p>
<h2>5.3  Misuse, Abuse and Diversion of Opioids</h2>
<p class="First">DILAUDID INJECTION and DILAUDID-HP INJECTION contain hydromorphone, an opioid agonist with an abuse liability similar to morphine, and a Schedule II, controlled substance. Hydromorphone has the potential for being abused, is sought by drug abusers and people with addiction disorders, and is subject to criminal diversion. Diversion of Schedule II products is an act subject to criminal penalty. </p>
<p>Abuse of DILAUDID INJECTION and DILAUDID-HP INJECTION, poses a hazard of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. This risk is increased with concurrent abuse of alcohol or other substances. Schedule II opioid agonists have the highest potential for abuse and risk of fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<p>DILAUDID INJECTION and DILAUDID-HP INJECTION can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing DILAUDID INJECTION and DILAUDID-HP INJECTION in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion.</p>
<p>Concerns about abuse, addiction, and diversion should not prevent the proper management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Healthcare professionals should contact their State Professional Licensing Board or State Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this product.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-6.4"></a><p></p>
<h2>5.4  Interactions with Alcohol and other CNS Depressants </h2>
<p class="First">The concurrent use of DILAUDID INJECTION or DILAUDID-HP INJECTION with other central nervous system (CNS) depressants, including, but not limited to, other opioids, illicit drugs, sedatives, hypnotics, general anesthetics, phenothiazines, muscle relaxants, other tranquilizers, and alcohol, increases the risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and profound sedation, potentially resulting in <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Use with caution and in reduced dosages in patients taking CNS depressants.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-6.5"></a><p></p>
<h2>5.5  Neonatal Withdrawal Syndrome</h2>
<p class="First">Infants born to mothers physically dependent on DILAUDID INJECTION or DILAUDID-HP INJECTION will also be physically dependent and may exhibit signs of withdrawal. The withdrawal signs include <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> reflexes, increased <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, increased stools, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose. Neonatal opioid withdrawal syndrome may be life-threatening and should be treated according to protocols developed by neonatology experts <span class="Italics"><span class="Emphasis">[see DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span> <a href="#Section_9.3">(9.3)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-6.6"></a><p></p>
<h2>5.6  Use in <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span> or <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span></h2>
<p class="First">The respiratory depressant effects of DILAUDID INJECTION and DILAUDID-HP INJECTION promote <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> retention which results in elevation of cerebrospinal fluid pressure. This increase in intracranial pressure may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, intracranial lesions, or other conditions that predispose patients to <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>.</p>
<p>DILAUDID INJECTION and DILAUDID-HP INJECTION may produce effects on pupillary response and consciousness which can obscure the clinical course and neurologic signs of further increase in pressure in patients with head injuries.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.7"></a><a name="section-6.7"></a><p></p>
<h2>5.7  Hypotensive Effect</h2>
<p class="First">DILAUDID INJECTION and DILAUDID-HP INJECTION may cause severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in patients whose ability to maintain blood pressure is compromised by a depleted blood volume, or a concurrent administration of drugs such as phenothiazines, general anesthetics, or other agents which compromise vasomotor tone <span class="Italics"><span class="Emphasis">[see DRUG INTERACTIONS <a href="#Section_7.1">(7.1)</a>]</span></span>.</p>
<p>DILAUDID INJECTION and DILAUDID-HP INJECTION may produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> in ambulatory patients.</p>
<p>Administer DILAUDID INJECTION and DILAUDID-HP INJECTION with caution to patients in circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, since vasodilation produced by the drug may further reduce <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and blood pressure. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.8"></a><a name="section-6.8"></a><p></p>
<h2>5.8  Sulfites</h2>
<p class="First">DILAUDID INJECTION and DILAUDID-HP INJECTION contain sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in nonasthmatic people. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.9"></a><a name="section-6.9"></a><p></p>
<h2>5.9  Use in Pancreatic/<span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">Biliary Tract Disease</span> and Other Gastrointestinal Conditions</h2>
<p class="First">The administration of DILAUDID INJECTION or DILAUDID-HP INJECTION may obscure the diagnosis or clinical course in patients with acute abdominal conditions <span class="Italics"><span class="Emphasis">[see CONTRAINDICATIONS <a href="#Section_4">(4.0)</a>]</span></span>.</p>
<p>Use DILAUDID INJECTION and DILAUDID-HP with caution in patients who are at risk of developing <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>.</p>
<p>Use DILAUDID INJECTION and DILAUDID-HP INJECTION with caution in patients with <span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">biliary tract disease</span>, including <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>, as hydromorphone may cause spasm of the sphincter of Oddi and diminish biliary and pancreatic secretions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.10"></a><a name="section-6.10"></a><p></p>
<h2>5.10  Special Risk Patients</h2>
<p class="First">Give DILAUDID INJECTION and DILAUDID-HP INJECTION with caution and the initial dose should be reduced in the elderly or debilitated and those with severe impairment of hepatic, pulmonary, or renal function; <span class="product-label-link" type="condition" conceptid="4182596" conceptname="Myxedema">myxedema</span> or <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>; adrenocortical insufficiency (e.g., Addison's Disease); <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; toxic psychoses; <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>; acute <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>; <span class="product-label-link" type="condition" conceptid="377830" conceptname="Alcohol withdrawal delirium">delirium tremens</span>; or kyphoscoliosis associated with <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<p>The administration of opioid analgesics including DILAUDID INJECTION and DILAUDID-HP INJECTION may aggravate preexisting <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>.</p>
<p>DILAUDID INJECTION and DILAUDID-HP INJECTION, as with other opioids, may aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>, and may induce or aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in some clinical settings.</p>
<p>Reports of mild to severe <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span> have been reported in severely compromised patients administered high doses of parenteral hydromorphone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.11"></a><a name="section-6.11"></a><p></p>
<h2>5.11  Use in Drug and Alcohol Dependent Patients </h2>
<p class="First">Use DILAUDID INJECTION and DILAUDID-HP INJECTION with caution in patients with <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span> and other drug dependencies due to the increased frequency of opioid tolerance, <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and the risk of addiction observed in these patient populations. Abuse of DILAUDID INJECTION or DILAUDID-HP INJECTION in combination with other CNS depressant drugs can result in serious risk to the patient.</p>
<p>DILAUDID INJECTION and DILAUDID-HP INJECTION contain hydromorphone, an opioid with no approved use in the management of addiction disorders. Its proper usage in individuals with drug or alcohol <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, either active or in remission, is for the management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> requiring opioid <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.12"></a><a name="section-6.12"></a><p></p>
<h2>5.12  Use in Ambulatory Patients</h2>
<p class="First">DILAUDID INJECTION and DILAUDID-HP INJECTION may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating machinery). Patients should be cautioned accordingly. DILAUDID INJECTION and DILAUDID-HP INJECTION may produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> in ambulatory patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.13"></a><a name="section-6.13"></a><p></p>
<h2>5.13  Parenteral Administration</h2>
<p class="First">DILAUDID INJECTION may be given intravenously, but the injection should be given very slowly. Rapid intravenous injection of opioid analgesics increases the possibility of side effects such as <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> <span class="Italics"><span class="Emphasis">[see DOSAGE AND ADMINSTRATION <a href="#Section_2.3">(2.3)</a>]</span></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-7"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>Serious adverse reactions associated with DILAUDID INJECTION and DILAUDID-HP INJECTION include <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> and, to a lesser degree, circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.</p>
<p><span class="Bold"><span class="Emphasis">The following serious adverse reactions described elsewhere in the labeling include:</span></span></p>
<dl class="None">
<dt>-</dt>
<dd><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> and secondary effects on intracranial pressure <span class="Italics"><span class="Emphasis">[see WARNINGS AND PRECAUTIONS <a href="#Section_5.2">(5.2</a>, <a href="#Section_5.6">5.6)</a>]</span></span>
</dd>
<dt>-</dt>
<dd><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> <span class="Italics"><span class="Emphasis">[see WARNINGS AND PRECAUTIONS <a href="#Section_5.7">(5.7)</a>]</span></span>
</dd>
<dt>-</dt>
<dd>Gastrointestinal effects and effects in sphincter of Oddi <span class="Italics"><span class="Emphasis">[see WARNINGS AND PRECAUTIONS <a href="#Section_5.9">(5.9)</a>]</span></span>
</dd>
<dt>-</dt>
<dd>Drug abuse, addiction, and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> <span class="Italics"><span class="Emphasis">[see DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span> <a href="#Section_9.2">(9.2</a>, <a href="#Section_9.3">9.3)</a>]</span></span>
</dd>
<dt>-</dt>
<dd>Effects on the ability to drive and operate machinery <span class="Italics"><span class="Emphasis">[see WARNINGS AND PRECAUTIONS <a href="#Section_5.12">(5.12)</a>]</span></span>
</dd>
</dl>
<p>The most common adverse effects are <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. These effects seem to be more prominent in ambulatory patients and in those not experiencing severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p><span class="Bold"><span class="Emphasis">Less Frequently Observed Adverse Reactions </span></span></p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>:</span></span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span></p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>:</span></span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span> </p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span></span> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p>
<p><span class="Bold"><span class="Emphasis">General disorders and administration site conditions:</span></span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">feeling abnormal</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4318392" conceptname="Injection site urticaria">injection site urticaria</span></p>
<p><span class="Bold"><span class="Emphasis">Hepatobiliary disorders:</span></span> <span class="product-label-link" type="condition" conceptid="4291807" conceptname="Biliary colic">biliary colic</span></p>
<p><span class="Bold"><span class="Emphasis">Metabolism and nutrition disorders:</span></span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span></p>
<p><span class="Bold"><span class="Emphasis">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>:</span></span> <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span></p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span></span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste alteration</span>, involuntary muscle contractions, <span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">presyncope</span></p>
<p><span class="Bold"><span class="Emphasis">Psychiatric disorders:</span></span> <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood altered</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span></p>
<p><span class="Bold"><span class="Emphasis">Renal and urinary disorders:</span></span> <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitation</span>, antidiuretic effects</p>
<p><span class="Bold"><span class="Emphasis">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span></span> <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span></p>
<p><span class="Bold"><span class="Emphasis">Skin and subcutaneous tissue disorders:</span></span> <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span></p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>:</span></span> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-7.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold"><span class="Emphasis">Postmarketing Experience</span></span></p>
<p>The following adverse reactions have been identified during post-approval use of hydromorphone. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, hepatic enzymes increased, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperalgesia</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, oropharyngeal <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-8"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-8.1"></a><p></p>
<h2>7.1  Drug Interactions with other CNS Depressants </h2>
<p class="First">DILAUDID INJECTION and DILAUDID-HP INJECTION should be used with caution and in reduced dosages when administered to patients concurrently receiving other central nervous system depressants including sedatives or hypnotics, general anesthetics, phenothiazines, centrally acting anti-emetics, tranquilizers, and alcohol because <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and profound sedation or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> may result. </p>
<p>When such combined therapy is contemplated, the dose of one or both agents should be reduced. Opioid analgesics, including DILAUDID INJECTION and DILAUDID-HP INJECTION, may enhance the action of neuromuscular blocking agents and produce an increased degree of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-8.2"></a><p></p>
<h2>7.2  Interactions with Mixed Agonist/Antagonist Opioid Analgesics </h2>
<p class="First">Agonist/antagonist analgesics (e.g., pentazocine, nalbuphine, and butorphanol) and partial agonist analgesics (buprenorphine) should be administered with caution to a patient who has received or is receiving a course of therapy with a pure opioid agonist analgesic such as DILAUDID INJECTION and DILAUDID-HP INJECTION. In this situation, mixed agonist/antagonist analgesics may reduce the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of DILAUDID INJECTION and DILAUDID-HP INJECTION and/or may precipitate withdrawal symptoms in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.3"></a><a name="section-8.3"></a><p></p>
<h2>7.3  Monoamine Oxidase Inhibitors (MAOIs)</h2>
<p class="First">MAOIs may potentiate the action of DILAUDID INJECTION and DILAUDID-HP INJECTION. Allow at least 14 days after stopping treatment with MAOIs before initiating treatment with DILAUDID INJECTION and DILAUDID-HP INJECTION. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.4"></a><a name="section-8.4"></a><p></p>
<h2>7.4  Anticholinergics</h2>
<p class="First">Anticholinergics or other medications with anticholinergic activity when used concurrently with DILAUDID INJECTION and DILAUDID-HP INJECTION may result in increased risk of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> and severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, which may lead to <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-9"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-9.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First">Teratogenic Effects</p>
<p>Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. Hydromorphone crosses the placenta. DILAUDID INJECTION or DILAUDID-HP INJECTION should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>No effects on <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or embryotoxicity were observed in pregnant rats given oral doses up to 7 mg/kg/day which is 3-fold higher than the human dose of 24 mg DILAUDID INJECTION (4 mg every 4 hours), on a body surface area basis.  Hydromorphone administration to pregnant Syrian hamsters and CF-1 mice during major organ development revealed teratogenic effects likely the result of maternal toxicity associated with sedation and <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>.  In Syrian hamsters given single subcutaneous doses from 14 to 258 mg/kg during organogenesis (gestation days 8-10), doses ≥ 19 mg/kg of hydromorphone produced skull malformations (<span class="product-label-link" type="condition" conceptid="4309376" conceptname="Exencephaly">exencephaly</span> and cranioschisis).  In CF-1 mice, continuous infusion of hydromorphone (≥ 15 mg/kg over 24 hours) via implanted osmotic pumps during organogenesis (gestation days 7-10) produced soft tissue malformations (<span class="product-label-link" type="condition" conceptid="437655" conceptname="Undescended testicle">cryptorchidism</span>, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, malformed ventricles and retina), and skeletal variations (split supraoccipital, checkerboard and split sternebrae, delayed ossification of the paws and ectopic ossification sites).  The malformations and variations observed in the hamsters and mice were observed at doses approximately 6-fold and 3-fold higher, respectively, than the human dose of 24 mg DILAUDID INJECTION (4 mg every 4 hours) on a body surface area basis.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="Section_8.2"></a><a name="section-9.2"></a><p></p>
<h2>8.2  Labor and Delivery</h2>
<p class="First">DILAUDID should be used with caution during labor. Opioids cross the placenta and may produce <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and physiologic effects in neonates. Sinusoidal fetal heart rate patterns may occur with the use of opioid analgesics.</p>
<p>Occasionally, opioid analgesics, including DILAUDID INJECTION and DILAUDID-HP INJECTION, may prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilatation, which tends to shorten labor.</p>
<p>Opioid analgesics, including DILAUDID INJECTION and DILAUDID-HP INJECTION, may cause <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the newborn. Closely observe neonates whose mothers received opioid analgesics during labor for signs of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Have a specific opioid antagonist, such as naloxone or nalmefene, available for reversal of opioid-induced <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the neonate. </p>
<p>Neonates whose mothers have been taking opioids chronically may also exhibit withdrawal signs, either at birth or in the nursery, because they have developed physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. This is not, however, synonymous with addiction <span class="Italics"><span class="Emphasis">[see DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span> <a href="#Section_9.3">(9.3)</a>]</span></span>. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening and should be treated according to protocols developed by neonatology experts <span class="Italics"><span class="Emphasis">[see WARNINGS AND PRECAUTIONS <a href="#Section_5.3">(5.3)</a>]</span></span>.<br>
								The effect of DILAUDID, if any, on the later growth, development, and functional maturation of the child is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-9.3"></a><p></p>
<h2>8.3  Nursing Mothers</h2>
<p class="First">Low levels of opioid analgesics have been detected in human milk. As a general rule, nursing should not be undertaken while a patient is receiving DILAUDID INJECTION or DILAUDID-HP INJECTION since it, and other drugs in this class, may be excreted in the milk.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-9.4"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First">The safety and effectiveness of DILAUDID INJECTION and DILAUDID-HP INJECTION in pediatric patients has not been established. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-9.5"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First">Clinical studies of DILAUDID INJECTION and DILAUDID-HP INJECTION did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is the chief risk in elderly or debilitated patients, usually the result of large initial doses in non opioid-tolerant patients. Titration in these patients should proceed cautiously <span class="Italics"><span class="Emphasis">[see DOSAGE AND ADMINISTRATION <a href="#Section_2.4">(2.4)</a> and WARNINGS AND PRECAUTIONS <a href="#Section_5.10">(5.10)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-9.6"></a><p></p>
<h2>8.6  Renal Impairment</h2>
<p class="First">The pharmacokinetics of hydromorphone following an oral administration of hydromorphone at a single 4 mg dose (2 mg hydromorphone immediate-release tablets) are affected by <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Mean exposure to hydromorphone (C<span class="Sub">max</span> and AUC<span class="Sub">0-∞</span>) is increased by 2-fold in patients with moderate (CLcr = 40 - 60 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and increased by 4-fold in patients with severe (CLcr &lt; 30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared with normal subjects (CLcr &gt; 80 mL/min). In addition, in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, hydromorphone appeared to be more slowly eliminated with a longer terminal elimination half-life (40 hr) compared to patients with normal renal function (15 hr). Start patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on one-fourth to one-half the usual starting dose depending on the degree of impairment. Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should be closely monitored during dose titration <span class="Italics"><span class="Emphasis">[see CLINICAL PHARMACOLOGY <a href="#Section_12.2">(12.2)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.7"></a><a name="section-9.7"></a><p></p>
<h2>8.7  Hepatic Impairment</h2>
<p class="First">The pharmacokinetics of hydromorphone following an oral administration of hydromorphone at a single 4 mg dose (2 mg hydromorphone immediate-release tablets) are affected by <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Mean exposure to hydromorphone (C<span class="Sub">max</span> and AUC<span class="Sub">∞</span>) is increased 4-fold in patients with moderate (Child-Pugh Group B) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared with subjects with normal hepatic function. Due to increased exposure of hydromorphone, patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should be started at one-fourth to one-half the recommended starting dose depending on the degree of hepatic dysfunction and closely monitored during dose titration. The pharmacokinetics of hydromorphone in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has not been studied. A further increase in C<span class="Sub">max</span> and AUC of hydromorphone in this group is expected and should be taken into consideration when selecting a starting dose <span class="Italics"><span class="Emphasis">[see CLINICAL PHARMACOLOGY <a href="#Section_12.2">(12.2)</a>]</span></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="Section_9"></a><a name="section-10"></a><p></p>
<h1>9  DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="Section_9.1"></a><a name="section-10.1"></a><p></p>
<h2>9.1  Controlled Substance</h2>
<p class="First"><span class="Bold"><span class="Emphasis">DILAUDID INJECTION and DILAUDID-HP INJECTION contain hydromorphone, which is a Schedule II controlled substance with an abuse liability similar to morphine. DILAUDID can be abused and is subject to criminal diversion. </span></span></p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="Section_9.2"></a><a name="section-10.2"></a><p></p>
<h2>9.2  Abuse</h2>
<p class="First">DILAUDID INJECTION and DILAUDID-HP INJECTION are intended for parenteral use only under the direct supervision of an appropriately licensed health care professional.</p>
<p>Abuse of DILAUDID INJECTION and DILAUDID-HP INJECTION poses a hazard of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. This risk is increased with concurrent abuse of alcohol or other substances. Parenteral drug abuse is commonly associated with transmission of infectious diseases, such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and HIV.</p>
<p>DILAUDID INJECTION and DILAUDID-HP INJECTION can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing, dispensing, ordering, or administering DILAUDID INJECTION or DILAUDID-HP INJECTION in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. Prescribers should monitor all patients receiving opioids for signs of abuse, misuse, and addiction. Furthermore, patients should be assessed for their potential for <span class="product-label-link" type="condition" conceptid="436954" conceptname="Drug abuse">opioid abuse</span> prior to being prescribed opioid therapy. Persons at increased risk for <span class="product-label-link" type="condition" conceptid="436954" conceptname="Drug abuse">opioid abuse</span> include those with a personal or family history of <span class="product-label-link" type="condition" conceptid="4279309" conceptname="Substance abuse">substance abuse</span> (including drug or <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span>) or mental illness (e.g., <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>). Opioids may still be appropriate for use in these patients, however, they will require intensive monitoring for indications of abuse. </p>
<p>Opioid drugs are sought by people with substance use disorders (abuse or addiction, the latter of which is also called “substance dependence?) and criminals who supply them by diverting medicines out of legitimate distribution channels. DILAUDID INJECTION and DILAUDID-HP INJECTION are targets for diversion. </p>
<p>“Drug-seeking? behavior is very common in persons with substance use disorders. Drug-seeking tactics include, but are not limited to, emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated “loss? of prescriptions, altering or forging of prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). “Doctor shopping? to obtain additional prescriptions is common among people with untreated substance use disorders and criminals who divert controlled substances.</p>
<p>The risks of misuse and abuse should be considered when prescribing or dispensing DILAUDID INJECTION or DILAUDID-HP INJECTION. Concerns about abuse and addiction, should not prevent the proper management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, however. Treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> should be individualized, balancing the potential benefits and risks for each patient. </p>
<p>Addiction is defined as a chronic, neurobiological disorder with genetic, psychosocial, and environmental aspects, characterized by one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a treatable disease, utilizing a multidisciplinary approach, but relapse is common. </p>
<p>Abuse and addiction are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in all addicts. In addition, abuse of opioids can occur in the absence of addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. Careful record keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised. </p>
<p>Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, proper dispensing and correct storage and handling are appropriate measures that help to limit misuse and abuse of opioid drugs. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.</p>
<p>Healthcare professionals should contact their State Professional Licensing Board or State Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this product.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="Section_9.3"></a><a name="section-10.3"></a><p></p>
<h2>9.3  Dependence</h2>
<p class="First">Tolerance to opioids is demonstrated by the need for increasing doses to maintain a defined effect such as <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> (in the absence of disease progression or other external factors). Tolerance to different effects of opioids may develop to varying degrees and at varying rates in a given individual. There is also inter-patient variability in the rate and extent of tolerance that develops to various opioid effects, whether the effect is desirable (e.g., <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>) or undesirable (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>). In general, patients taking opioid analgesics that are appropriately titrated for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> control develop tolerance to the respiratory depressant effects fairly reliably. Conversely, tolerance to the constipating effects of opioids rarely develops, even when they are administered over long periods of time.</p>
<p>Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance are not unusual during chronic opioid therapy. </p>
<p>The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, perspiration, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>. Other signs and symptoms also may develop, including: <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, or heart rate. </p>
<p>In general, opioids used regularly should not be abruptly discontinued.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-11"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10.1"></a><a name="section-11.1"></a><p></p>
<h2>10.1  Signs and Symptoms</h2>
<p class="First">Signs and symptoms of acute overdosage with DILAUDID INJECTION or DILAUDID-HP INJECTION include: <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">constricted pupils</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, partial or complete airway obstruction, atypical <span class="product-label-link" type="condition" conceptid="4248728" conceptname="Snoring">snoring</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Hydromorphone may cause <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, even in total darkness. Pinpoint pupils are a sign of opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> but are not pathognomonic (pontine lesions of hemorrhagic or ischemic origin may produce similar findings). Marked <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, rather than <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, may be seen with <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situations.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10.2"></a><a name="section-11.2"></a><p></p>
<h2>10.2  Treatment</h2>
<p class="First">In the treatment of overdosage, primary attention should be given to the reestablishment of a patent airway and institution of assisted or controlled ventilation. Supportive measures (including oxygen, vasopressors) should be employed in the management of circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> accompanying <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> as indicated. <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span> or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> may require cardiac massage or defibrillation.</p>
<p>The opioid antagonist, naloxone, is a specific antidote against <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which may result from overdosage, or unusual sensitivity to DILAUDID INJECTION or DILAUDID-HP INJECTION. Therefore, an appropriate dose of this antagonist should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. Naloxone should not be administered in the absence of clinically significant respiratory or circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Naloxone should be administered cautiously to persons who are known, or suspected, to be physically dependent on DILAUDID INJECTION or DILAUDID-HP INJECTION. In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute withdrawal syndrome.</p>
<p>Since the duration of action of DILAUDID INJECTION and DILAUDID-HP INJECTION may exceed that of the antagonist, the patient should be kept under continued surveillance; repeated doses of the antagonist may be required to maintain adequate respiration. Apply other supportive measures when indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-12"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">DILAUDID (hydromorphone hydrochloride), a hydrogenated ketone of morphine, is an opioid analgesic. The chemical name of DILAUDID is 4,5α-epoxy-3-hydroxy-17-methylmorphinan-6-one hydrochloride. The structural formula is: </p>
<p><img alt="Dilaudid Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c88f81ac-1643-4c08-ae2c-63cbe956db7e&amp;name=diluadid-struct.jpg"></p>
<p><span class="Bold"><span class="Emphasis">C<span class="Sub">17</span>H<span class="Sub">19</span>NO<span class="Sub">3</span>•HCl                            321.80</span></span></p>
<p>DILAUDID INJECTION is available as a sterile, aqueous solution in COLORLESS ampules for parenteral administration. Each 1 mL ampule contains 1 mg, 2 mg, or 4 mg of hydromorphone hydrochloride with 0.2% sodium citrate and 0.2% citric acid added as a buffer to maintain a pH between 3.5 and 5.5.</p>
<p>DILAUDID-HP INJECTION is available as a sterile, aqueous solution in <span class="Underline"><span class="Emphasis">AMBER</span></span> ampules and in <span class="Underline"><span class="Emphasis">AMBER</span></span>, single-dose vials for intravenous, subcutaneous, or intramuscular administration. Each ampule and single-dose vial contains 10 mg/mL of hydromorphone hydrochloride with 0.2% sodium citrate and 0.2% citric acid  added as a buffer to maintain a pH of between 3.5 and 5.5. The single dose vials are capped with stoppers containing natural rubber latex. </p>
<p>DILAUDID-HP INJECTION is also available as sterile, lyophilized powder in an <span class="Underline"><span class="Emphasis">AMBER</span></span>, single-dose vial for reconstitution for intravenous, subcutaneous, or intramuscular administration. Each single dose vial contains 250 mg sterile, lyophilized hydromorphone HCl with either hydrochloric acid or sodium hydroxide added to adjust the pH. Each vial is to be reconstituted with 25 mL of Sterile Water for Injection USP to provide a solution containing 10 mg/mL with a pH between 4.5 and 6.5. The single dose vials are capped with stoppers containing natural rubber latex.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-13"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-13.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">The precise mode of analgesic action of opioid analgesics is unknown. However, specific CNS opiate receptors have been identified. Opioids are believed to express their pharmacological effects by combining with these receptors. </p>
<p>Hydromorphone hydrochloride is a mu-opioid receptor agonist whose principal therapeutic action is <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.  Other members of the class known as opioid agonists include substances such as morphine, oxycodone, fentanyl, codeine, hydrocodone, and oxymorphone. </p>
<p><span class="Underline"><span class="Emphasis">Central Nervous System</span></span></p>
<p>Pharmacological effects of opioid agonists include anxiolysis, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, feelings of relaxation, and <span class="product-label-link" type="condition" conceptid="4009383" conceptname="Cough suppression">cough suppression</span>, as well as <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</p>
<p>Hydromorphone produces <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by direct effect on brain stem respiratory centers. The mechanism of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> also involves a reduction in the responsiveness of the brain stem respiratory centers to increases in <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>.</p>
<p>Hydromorphone causes <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>. Pinpoint pupils are a common sign of opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> but are not pathognomonic (pontine lesions of hemorrhagic or ischemic origin may produce similar findings). </p>
<p><span class="Underline"><span class="Emphasis">Gastrointestinal Tract and Other Smooth Muscle </span></span></p>
<p>Gastric, biliary and pancreatic secretions are decreased by opioids such as hydromorphone. Hydromorphone causes a reduction in motility associated with an increase in tone in the gastric antrum and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, and tone may be increased to the point of spasm. The end result is <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Hydromorphone can cause a marked increase in biliary tract pressure as a result of spasm of the sphincter of Oddi. </p>
<p><span class="Underline"><span class="Emphasis">Cardiovascular System</span></span></p>
<p>Hydromorphone may produce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> as a result of either peripheral vasodilation, release of histamine, or both. Other manifestations of histamine release and/or peripheral vasodilation may include <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eyes</span>. </p>
<p>Effects on the myocardium after intravenous administration of opioids are not significant in normal persons, vary with different opioid analgesic agents and vary with the hemodynamic state of the patient, state of hydration and sympathetic drive. </p>
<p><span class="Underline"><span class="Emphasis">Endocrine System</span></span></p>
<p>Opioids may influence the hypothalamic-pituitary-adrenal or -gonadal axes. Some changes that can be seen include an increase in serum prolactin, and decreases in plasma cortisol and testosterone. Clinical signs and symptoms may be manifest from these hormonal changes.</p>
<p><span class="Underline"><span class="Emphasis">Immune System</span></span></p>
<p>In vitro and animal studies indicate that opioids have a variety of effects on immune functions. The clinical significance of these findings is unknown.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.2"></a><a name="section-13.2"></a><p></p>
<h2>12.2  Pharmacokinetics</h2>
<p class="First"><span class="Underline"><span class="Emphasis">Distribution</span></span></p>
<p>At therapeutic plasma levels, hydromorphone is approximately 8-19% bound to plasma proteins. After an intravenous bolus dose, the steady state of volume of distribution [mean (%CV)] is 302.9 (32%) liters. </p>
<p><span class="Underline"><span class="Emphasis">Metabolism</span></span></p>
<p>Hydromorphone is extensively metabolized via glucuronidation in the liver, with greater than 95% of the dose metabolized to hydromorphone-3-glucuronide along with minor amounts of 6-hydroxy reduction metabolites. </p>
<p><span class="Underline"><span class="Emphasis">Elimination</span></span></p>
<p>Only a small amount of the hydromorphone dose is excreted unchanged in the urine. Most of the dose is excreted as hydromorphone-3-glucuronide along with minor amounts of 6-hydroxy reduction metabolites. The systemic clearance is approximately 1.96 (20%) liters/minute. The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours. </p>
<p><span class="Underline"><span class="Emphasis">Special Populations</span></span></p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></p>
<p>After oral administration of hydromorphone at a single 4 mg dose (2 mg hydromorphone immediate-release tablets), mean exposure to hydromorphone (C<span class="Sub">max</span> and AUC<span class="Sub">∞</span>) is increased 4-fold in patients with moderate (Child-Pugh Group B) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared with subjects with normal hepatic function. Patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should be started at one-fourth to one-half the recommended starting dose and closely monitored during dose titration. The pharmacokinetics of hydromorphone in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has not been studied. A further increase in C<span class="Sub">max</span> and AUC of hydromorphone in this group is expected and should be taken into consideration when selecting a starting dose <span class="Italics"><span class="Emphasis">[see USE IN SPECIFIC POPULATIONS <a href="#Section_8.7">(8.7)</a>]</span></span>.</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p>The pharmacokinetics of hydromorphone following an oral administration of hydromorphone at a single 4 mg dose (2 mg hydromorphone immediate-release tablets) are affected by <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Mean exposure to hydromorphone (C<span class="Sub">max</span> and AUC<span class="Sub">0-∞</span>) is increased by 2-fold in patients with moderate (CLcr = 40 - 60 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and increased by 4-fold in patients with severe (CLcr &lt; 30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared with normal subjects (CLcr &gt; 80 mL/min). In addition, in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, hydromorphone appeared to be more slowly eliminated with a longer terminal elimination half-life (40 hr) compared to patients with normal renal function (15 hr). Start patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on one-fourth to one-half the usual starting dose depending on the degree of impairment. Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should be closely monitored during dose titration <span class="Italics"><span class="Emphasis">[see USE IN SPECIFIC POPULATIONS <a href="#Section_8.6">(8.6)</a>] </span></span>.</p>
<p><span class="Italics"><span class="Emphasis">Pediatrics</span></span></p>
<p>Pharmacokinetics of hydromorphone have not been evaluated in children.</p>
<p><span class="Italics"><span class="Emphasis">Geriatric</span></span></p>
<p>In the geriatric population, age has no effect on the pharmacokinetics of hydromorphone.</p>
<p><span class="Italics"><span class="Emphasis">Gender</span></span></p>
<p>Gender has little effect on the pharmacokinetics of hydromorphone. Females appear to have a higher C<span class="Sub">max</span> (25%) than males with comparable AUC<span class="Sub">0-24</span> values. The difference observed in C<span class="Sub">max</span> may not be clinically relevant. </p>
<p><span class="Italics"><span class="Emphasis">Race</span></span></p>
<p>The effect of race on hydromorphone pharmacokinetics has not been studied.</p>
<p><span class="Italics"><span class="Emphasis">Pregnancy and Nursing Mothers</span></span></p>
<p>Hydromorphone crosses the placenta. Hydromorphone is also found in low levels in breast milk, and may cause respiratory compromise in newborns when administered during labor or delivery.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-14"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-14.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Underline"><span class="Emphasis">Carcinogenesis</span></span></p>
<p>Long term studies in animals to evaluate the carcinogenic potential of hydromorphone have not been conducted.</p>
<p><span class="Underline"><span class="Emphasis">Mutagenesis</span></span></p>
<p>Hydromorphone was not mutagenic in the <span class="Italics"><span class="Emphasis">in vitro</span></span> bacterial reverse mutation assay (Ames assay). Hydromorphone was not clastogenic in either the <span class="Italics"><span class="Emphasis">in vitro</span></span> human lymphocyte chromosome aberration assay or the <span class="Italics"><span class="Emphasis">in vivo</span></span> mouse micronucleus assay.</p>
<p><span class="Underline"><span class="Emphasis">Impairment of Fertility</span></span></p>
<p>No effects on fertility, reproductive performance, or reproductive organ morphology were observed in male or female rats given oral doses up to 7 mg/kg/day which is 3-fold higher than the human dose of 24 mg DILAUDID INJECTION (4 mg every 4 hours), on a body surface area basis. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-15"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesic effects</span> of single doses of DILAUDID ORAL LIQUID administered to patients with post-surgical <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> have been studied in double-blind controlled trials. In one study, both 5 mg and 10 mg of DILAUDID ORAL LIQUID provided significantly more <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> than placebo. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-16"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_16.1"></a><a name="section-16.1"></a><p></p>
<h2>16.1  Safety and Handling Instructions</h2>
<p class="First">DILAUDID INJECTION and DILAUDID-HP INJECTION pose little risk of direct exposure to health care personnel and should be handled and disposed of prudently in accordance with hospital or institutional policy. When DILAUDID INJECTION or DILAUDID-HP INJECTION is no longer needed, any unused liquid should be destroyed by <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> it down the toilet. </p>
<p>Access to drugs with a potential for abuse such as DILAUDID INJECTION and DILAUDID-HP INJECTION presents an occupational hazard for addiction in the health care industry. Routine procedures for handling controlled substances developed to protect the public may not be adequate to protect health care workers. Implementation of more effective accounting procedures and measures to restrict access to drugs of this class (appropriate to the practice setting) may minimize the risk of self-administration by health care providers. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_16.2"></a><a name="section-16.2"></a><p></p>
<h2>16.2  How Supplied</h2>
<p class="First"><span class="Underline"><span class="Emphasis">DILAUDID INJECTION</span></span></p>
<p>DILAUDID INJECTION (hydromorphone hydrochloride) is supplied in COLORLESS ampules. Each 1 mL of sterile, aqueous solution contains 1 mg, 2 mg, or 4 mg hydromorphone hydrochloride with 0.2% sodium citrate and 0.2% citric acid solution. DILAUDID INJECTION contains no added preservative and is supplied as follows:</p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 59011-441-10: Box of ten 1 mL (1 mg/mL) ampules<br><span class="Bold"><span class="Emphasis">NDC</span></span> 59011-442-10: Box of ten 1 mL (2 mg/mL) ampules <br><span class="Bold"><span class="Emphasis">NDC</span></span> 59011-442-25: Box of twenty-five 1 mL (2 mg/mL) ampules<br><span class="Bold"><span class="Emphasis">NDC</span></span> 59011-444-10: Box of ten 1 mL (4 mg/mL) ampules</p>
<p><span class="Underline"><span class="Emphasis">DILAUDID-HP INJECTION</span></span></p>
<p>DILAUDID-HP INJECTION (hydromorphone hydrochloride) is supplied in <span class="Underline"><span class="Emphasis">AMBER</span></span> ampules, and <span class="Underline"><span class="Emphasis">AMBER</span></span> single-dose vials. Each ampule and single-dose vial of sterile aqueous solution contains 10 mg of hydromorphone hydrochloride with 0.2% sodium citrate and 0.2% citric acid solution. </p>
<p>DILAUDID-HP INJECTION Sterile Lyophilized Powder is supplied in an <span class="Underline"><span class="Emphasis">AMBER</span></span> single-dose vial. Each vial contains 250 mg of sterile, lyophilized hydromorphone hydrochloride.</p>
<p>DILAUDID-HP INJECTION contains no added preservative and is supplied as follows:</p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 59011-445-01: Box of ten 1 mL (10 mg/mL) ampules<br><span class="Bold"><span class="Emphasis">NDC</span></span> 59011-445-05: Box of ten 5 mL (10 mg/mL) ampules<br><br><span class="Sup">†</span><span class="Bold"><span class="Emphasis">NDC</span></span> 59011-445-50: One 50 mL (10 mg/mL) single-dose vial with black rubber stopper and white flip-top/tear-off seal.<br><span class="Sup">†</span><span class="Bold"><span class="Emphasis">NDC</span></span> 59011-446-25: One 250 mg single-dose vial with black rubber stopper and black flip-top seal.<br></p>
<p><span class="Bold"><span class="Emphasis"><span class="Sup">†</span>The Stoppers for These Products Contain Natural Rubber Latex</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_16.3"></a><a name="section-16.3"></a><p></p>
<h2>16.3  Storage</h2>
<p class="First">PROTECT FROM LIGHT. </p>
<p>Keep covered in carton until time of use. Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First">Healthcare professionals can telephone Purdue Pharma L.P.’s Medical Services Department (1-888-726-7535) for information on this product.</p>
<p><span class="Bold"><span class="Emphasis">CAUTION: DEA Order Form Required.</span></span></p>
<p>©2011 Purdue Pharma L.P.</p>
<p>Manufactured by<br>
						Hospira, Inc., Lake Forest, IL 60045, U.S.A. </p>
<p>For<br>
						Purdue Pharma L.P. Stamford, CT 06901-3431</p>
<p><span class="Italics"><span class="Emphasis">U.S. Patent Number 6,589,960</span></span></p>
<p>302703-0A</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_pdp1"></a><a name="section-18"></a><p></p>
<p class="First"> </p>
<p> </p>
<p>Box of ten 1 mg/mL ampules<br>
						NDC 59011-441-10</p>
<div class="Figure"><img alt="Dilaudid Injection 1 mg/mL NDC 59011-441-10" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c88f81ac-1643-4c08-ae2c-63cbe956db7e&amp;name=301784-0C%201mg%20mL%20label.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_pdp2"></a><a name="section-19"></a><p></p>
<p class="First"> </p>
<p>Box of ten 2 mg/mL ampules<br>
						NDC 59011-442-10</p>
<div class="Figure"><img alt="Dilaudid Injection 2 mg/mL NDC 59011-442-10 NDC 59011-442-25" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c88f81ac-1643-4c08-ae2c-63cbe956db7e&amp;name=301785-0C%202mg%20mL%2010s%20%20label.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_pdp3"></a><a name="section-20"></a><p></p>
<p class="First"> </p>
<p>Label for one 50mL Single Dose Vial<br></p>
<div class="Figure"><img alt="Label for one 50mL Single Dose Vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c88f81ac-1643-4c08-ae2c-63cbe956db7e&amp;name=301790-0D%2050%20mL%20vial%20label.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_pdp5"></a><a name="section-21"></a><p></p>
<p class="First"> </p>
<p>Box of ten 4 mg/mL ampules<br>
						NDC 59011-444-10</p>
<div class="Figure"><img alt="Dilaudid Injection 4 mg/mL NDC 59011-444-10" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c88f81ac-1643-4c08-ae2c-63cbe956db7e&amp;name=301787-0C%204mg%20mL%20label.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_pdp6"></a><a name="section-22"></a><p></p>
<p class="First"> </p>
<p>Box of ten 1mL (10 mg) ampules<br>
						NDC 59011-445-01</p>
<div class="Figure"><img alt="Dilaudid Injection 10 mg/mL NDC 59011-445-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c88f81ac-1643-4c08-ae2c-63cbe956db7e&amp;name=301788-0C%201mL%2010s%20label.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_pdp7"></a><a name="section-23"></a><p></p>
<p class="First"> </p>
<p>Dilaudid Injection 5 mg/mL<br>
						NDC 59011-445-50</p>
<div class="Figure"><img alt="Dilaudid Injection 5 mg/mL NDC 59011-445-50" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c88f81ac-1643-4c08-ae2c-63cbe956db7e&amp;name=301789-0C%205mL%20amp%2010s%20label.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_pdp8"></a><a name="section-24"></a><p></p>
<p class="First"> </p>
<p>Dilaudid Injection 250 mg/vial<br>
						NDC 59011-446-25</p>
<div class="Figure"><img alt="Dilaudid Injection 250 mg/vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c88f81ac-1643-4c08-ae2c-63cbe956db7e&amp;name=301791-0C%20250mg%20vial.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DILAUDID 		
					</strong><br><span class="contentTableReg">hydromorphone hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59011-441</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>hydromorphone hydrochloride</strong> (hydromorphone) </td>
<td class="formItem">hydromorphone hydrochloride</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59011-441-10</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 AMPULE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019034</td>
<td class="formItem">01/01/1926</td>
<td class="formItem">02/01/2017</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DILAUDID 		
					</strong><br><span class="contentTableReg">hydromorphone hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59011-442</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>hydromorphone hydrochloride</strong> (hydromorphone) </td>
<td class="formItem">hydromorphone hydrochloride</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59011-442-10</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 AMPULE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:59011-442-25</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 AMPULE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019034</td>
<td class="formItem">01/01/1926</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DILAUDID 		
					</strong><br><span class="contentTableReg">hydromorphone hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59011-444</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>hydromorphone hydrochloride</strong> (hydromorphone) </td>
<td class="formItem">hydromorphone hydrochloride</td>
<td class="formItem">4 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59011-444-10</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">4 mL in 1 AMPULE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019034</td>
<td class="formItem">01/01/1926</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DILAUDID HP 		
					</strong><br><span class="contentTableReg">hydromorphone hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59011-445</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>hydromorphone hydrochloride</strong> (hydromorphone) </td>
<td class="formItem">hydromorphone hydrochloride</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59011-445-01</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 AMPULE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:59011-445-05</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 AMPULE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:59011-445-50</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">50 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019034</td>
<td class="formItem">01/11/1984</td>
<td class="formItem">05/01/2016</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DILAUDID HP 		
					</strong><br><span class="contentTableReg">hydromorphone hydrochloride injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59011-446</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>hydromorphone hydrochloride</strong> (hydromorphone) </td>
<td class="formItem">hydromorphone hydrochloride</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59011-446-25</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">25 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019034</td>
<td class="formItem">01/11/1984</td>
<td class="formItem">07/01/2016</td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Purdue Pharma LP
							(932323652)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Purdue Pharma LP (932323652)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Hospira, Inc.</td>
<td class="formItem"></td>
<td class="formItem">030606222</td>
<td class="formItem">MANUFACTURE(59011-446, 59011-442, 59011-441, 59011-445, 59011-444)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Halo Pharmaceutical Inc.</td>
<td class="formItem"></td>
<td class="formItem">829609168</td>
<td class="formItem">API MANUFACTURE(59011-441, 59011-444, 59011-442, 59011-445, 59011-446)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7df19d43-f1bf-3a27-4e72-754fc918aefe</div>
<div>Set id: c88f81ac-1643-4c08-ae2c-63cbe956db7e</div>
<div>Version: 9</div>
<div>Effective Time: 20150904</div>
</div>
</div> <div class="DistributorName">Purdue Pharma LP</div></p>
</body></html>
